07:00 , Jun 28, 2012 |  BC Innovations  |  Strategy

Pharma compounds at the crossroads

The National Center for Advancing Translational Sciences (NCATS) has disclosed details about the first library of therapeutics in its Discovering New Therapeutic Uses for Existing Molecules program ( see "Repurposing pharma compounds"). The compounds provided...
07:00 , Aug 12, 2010 |  BC Innovations  |  Targets & Mechanisms

The GPCR-cancer connection

Researchers from Roche 's Genentech Inc. unit have identified a host of somatic mutations and gene copy number alterations across human cancers that represent potential targets for the disease. 1 Nineteen of the 112 candidate...
07:00 , Aug 27, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

Indication Target/marker/pathway Summary Licensing status Publication and contact nformation Endocrine disease Diabetes Cholecystokinin A receptor (CCKAR; CCK-A) Studies in rats suggest that enhancing cholecystokinin (CCK) signaling in the duodenum could help treat hyperglycemia associated with...
07:00 , Aug 27, 2009 |  BC Innovations  |  Targets & Mechanisms

Controlling the liver via the gut

Tim Fulmer, Senior Writer  Last year, University of Toronto researchers identified a circuit that allows lipid-sensing cells in the small intestine to act remotely through the brain to reduce hepatic glucose production after food intake....
07:00 , Mar 26, 2009 |  BC Innovations  |  Distillery Techniques

Technology: Imaging

This week in techniques Approach Summary Licensing status Publication and contact information Imaging Cholecystokinin receptor-selective labeling for in vivo tumor targeting Radioiodine-labeled benzodiazepines could be useful for in vivo identification of tumors that bind drugs...
07:00 , May 5, 2008 |  BC Week In Review  |  Company News

Entelos, Pfizer, California Institute of Technology, Massachusetts Institute of Technology, University of California, University of Massachusetts endocrine news

Pfizer entered a consortium with the universities and Entelos to re-examine the regulatory mechanisms of human energy metabolism. Pfizer will fully fund the three-year $14 million Insulin Resistance Pathway (IRP) Project. The first phase of...
07:00 , Oct 6, 2003 |  BC Week In Review  |  Clinical News

Dexloxiglumide: Phase III

In 2 placebo-controlled Phase III trials in more than 1,400 women, dexloxiglumide failed to meet the primary endpoint of subject global assessment, a measurement of a patient's overall evaluation of abdominal discomfort, pain and altered...
07:00 , Oct 1, 2003 |  BC Extra  |  Clinical News

Forest discontinues IBS compound

FRX discontinued development of dexloxiglumide to treat constipation predominant irritable bowel syndrome (IBS) based on results from two placebo-controlled Phase III trials in more than 1,400 women. The compound, a cholecystokinin (CCK1) receptor antagonist, failed...
08:00 , Nov 18, 2002 |  BioCentury  |  Product Development

Plumbing plays

Plumbing plays Company Product Description Indication Status Milestone Adolor Alvimopan Gut-specific mu opioid receptor antagonist Post-operative ileus (POI) and chronic opioid-induced bowel dysfunction (OBD) Ph III POI NDA 2H03 Alizyme ALT-1251 renzapride Mixed serotonin receptor...